摘要: |
目的观察长期吸入布地奈德福莫特罗粉吸入剂(信必可都保)对慢性阻塞性肺疾病(COPD)合并糖尿病患者糖代谢的影响。方法选择合并2型糖尿病的COPD稳定期患者100例,长期吸入信必可都保(160μg/次,2次/d),观察治疗前及治疗3、6、12个月后采用CAT量表评定的患者生活质量和糖代谢指标(空腹血糖、餐后2小时血糖、糖化血红蛋白、胰岛素、C肽)的变化。结果规律吸入信必可都保3、6、12个月后患者生活质量与治疗前比较差异有统计学意义(P<0.05),而糖代谢指标与治疗前比较差异无统计学意义(P>0.05)。结论长期吸入信必可都保不会引起合并2型糖尿病的COPD患者糖代谢异常。 |
关键词: 慢性阻塞性肺疾病 糖尿病 布地奈德 |
DOI: |
分类号: |
基金项目: |
|
Influence of Symbicort Inhalation Therapy on Blood Glucose in Patients with Chronic Obstructive Pulmonary Disease Complicated with Type 2 Diabetes Mellitus |
Duan Yongjian;Tang Zuhui;Chen Xubo
|
Qianwei County People’s Hospital
|
Abstract: |
Objective To observe the influence of long-term inhalation of Budesonide and Formoterol Inhalant Powder( Symbicort Turbuhaler) on glucometabolism in patients with chronic obstructive pulmonary disease( COPD) complicated with diabetes mellitus.Methods A total of 100 COPD patients during stable phase complicated with type 2 diabetes mellitus were enrolled in this study and received long-term inhalation of Symbicort Turbuhaler( 160μg each time and twice daily). The changes of living qualities and glucometabolism indicators( e.g.fasting blood glucose,2-hour postprandial blood glucose,glycosylated hemoglobin,insulin and C-peptide) evaluated by CAT scale between conditions before treatment and conditions 3,6 or 12 months after treatment,were observed and recorded.Results 3,6 and 12 months after regular inhalation of Symbicort Turbuhaler,living quality of patients had statistically significant difference with conditions before treatment( P<0. 05),while glucometabolism indicators showed no statistically significant difference with that before treatment( P > 0. 05). Conclusion Long-term inhalation of Symbicort Turbuhaler does not cause abnormal glucose metabolism in COPD patients compliated with type 2 diabetes mellitus |
Key words: chronicobstructivepulmonarydisease diabetesmellitus Budesonide |